Does Pillcheck test pharmacodynamic genes COMT and MTHFR?

No. Pillcheck’s test panel focuses on pharmacokinetic genes, which determine how your body metabolizes a medication, rather than pharmacodynamic genes, which relate to how a drug acts on the body. That’s why genes like COMT and MTHFR are not currently included in our panel. 

COMT and MTHFR are offered in some commercial pharmacogenomic (PGx) panels. They also come up frequently online — COMT in relation to stimulant medications like Adderall or Ritalin, and MTHFR in relation to depression treatment and folate metabolism. However, neither gene is supported by clinical pharmacogenetic guidelines. Here are a few key reasons why: 

• No guideline or regulatory support: There is no Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline, and no FDA drug label, that recommends COMT or MTHFR testing to guide medication selection or dosing. (CPIC/PharmGKB references for COMT)
  
  
• Lack of consistent evidence: Large, well-controlled studies haven’t shown that these genetic markers have a consistent, highly predictive value for how a patient will respond to a specific medication.
  
  
• Multifactorial nature: Treatment response depends on many complex factors, genetics included, but also dose, other medications, lifestyle, and the condition itself. Current pharmacodynamic markers only account for a small fraction of that variability.
  
  
• Some professional societies have cautioned against routine testing: For example, the American College of Medical Genetics and Genomics (ACMG) and the American College of Obstetricians and Gynecologists (ACOG) have specifically advised against routine MTHFR testing for other common indications (such as clotting risk or pregnancy loss workups), citing unproven clinical utility.
  
  
• Standard of care remains unchanged: The recommended approach for finding the right medication and dose remains careful clinical monitoring and adjustment under the guidance of a healthcare professional. 

What Pillcheck tests instead 

Pillcheck’s panel focuses on pharmacokinetic genes with robust, guideline-supported evidence, such as CYP2D6, CYP2C19, and CYP3A4, that are key for metabolism-based dosing of various medications, including many used in ADHD and mental health care. 

Related:

What genes does Pillcheck test? 

Does Pillcheck test pharmacodynamic genes?